Financial Position - Cibus reported a cash position of $9.9 million as of December 31, 2025, and expects existing cash to fund operations into late Q3 2026[21]. - Cibus' cash and cash equivalents decreased to $9.923 million as of December 31, 2025, down from $14.433 million a year earlier, a decline of approximately 31.5%[37]. - The company anticipates the need for additional near-term funding to finance its activities, indicating potential challenges in obtaining capital on acceptable terms[31]. Revenue and Loss - Net loss for the quarter ended December 31, 2025, was $31.9 million, an increase from $25.8 million in the same period last year, representing a year-over-year increase of approximately 23.9%[26]. - Total revenue for the quarter was $1.057 million, down from $1.212 million in the same quarter of 2024, reflecting a decrease of approximately 12.8%[41]. - Net loss for 2025 was $132,201, a significant improvement from a net loss of $282,713 in 2024, representing a reduction of approximately 53%[43]. Expenses - R&D expenses decreased to $9.4 million in Q4 2025 from $12.4 million in the previous year, reflecting cost reduction initiatives[21]. - SG&A expenses were reduced to $5.1 million in Q4 2025 compared to $6.8 million in the year-ago period, also due to cost-saving measures[21]. - Total operating expenses increased to $23.631 million from $19.236 million year-over-year, an increase of approximately 22.8%[41]. Assets and Liabilities - Total assets decreased to $305.047 million from $350.069 million year-over-year, a decline of approximately 12.9%[39]. - Total liabilities increased to $283.218 million from $252.238 million, reflecting an increase of approximately 12.3%[39]. Operational Highlights - The company achieved a significant milestone with its first customer payment from the Sustainable Ingredients program in Q4 2025, indicating strong commercial potential[6]. - Cibus' Rice program is on track for targeted launches in 2027 and 2028, with a potential for over $200 million in annual addressable royalties at peak[7]. - Cibus' single-cell editing system has achieved up to 50-70% efficiency, fundamentally changing breeding economics for seed companies[6]. Regulatory and Market Developments - The EU reached a political agreement on New Genomic Techniques legislation, a significant regulatory advancement that Cibus has influenced over the past decade[6]. - Cibus' Trait Machine process was recognized by Fast Company Magazine as one of the most innovative products in 2024, highlighting the company's advancements in gene editing technology[29]. Cash Flow and Financing - Net cash used in operating activities improved from $58,043 in 2024 to $50,591 in 2025, reflecting a decrease of approximately 13%[43]. - Proceeds from issuances of securities increased to $50,100 in 2025 from $43,902 in 2024, marking an increase of about 14%[43]. - Net cash provided by financing activities rose to $46,648 in 2025 compared to $40,598 in 2024, an increase of about 15%[43]. Impairments - Long-lived assets impairment was reported at $9.1 million for Q4 2025, attributed to the planned wind-down of operations at the Roseville facility[21]. - Goodwill impairment decreased from $181,432 in 2024 to $20,950 in 2025, indicating a reduction of about 88%[43].

Clinical Development - Haduvio achieved statistically significant reductions in 24-hour cough frequency of 60.2%, 53.4%, and 47.9% for the 108 mg, 54 mg, and 27 mg BID dose groups, respectively, compared to a placebo reduction of 16.9% in the Phase 2b CORAL trial[565]. - The first Phase 3 trial for Haduvio is planned to enroll approximately 300 patients and is set to initiate in the second quarter of 2026[566]. - The second Phase 3 trial is planned to enroll approximately 130 patients and is expected to start in the second half of 2026[566]. - The company plans to initiate a Phase 2b trial for Haduvio in RCC in the second quarter of 2026, subject to regulatory review[570]. - Haduvio's development costs include manufacturing necessary quantities for clinical trials and commercialization activities, with a focus on treatment for IPF-related chronic cough, non-IPF ILD, and RCC[609]. Financial Performance - The company reported a net loss of $42.759 million for the year ended December 31, 2025, a decrease from a net loss of $47.911 million in 2024, reflecting an improvement of $5.152 million[585]. - As of December 31, 2025, the company had an accumulated deficit of $329.8 million, primarily due to research and development and general and administrative expenses[572]. - Other income, net rose to $6.5 million in 2025 from $3.6 million in 2024, mainly due to increased interest income from higher cash equivalents and marketable securities[588]. - Net cash used in operating activities was $42.1 million in 2025, compared to $38.3 million in 2024, reflecting a net loss of $42.8 million[596]. - Net cash used in investing activities was $94.1 million in 2025, primarily due to $170.7 million in purchases of marketable securities[599]. - Net cash provided by financing activities was $121.0 million in 2025, mainly from the June 2025 Offering, which generated approximately $115.1 million in gross proceeds[591][601]. - The company reported a net decrease in cash and cash equivalents of $15.2 million in 2025, compared to an increase of $1.7 million in 2024[595]. Research and Development Expenses - Research and development expenses for 2025 were $33.478 million, a decrease of $5.899 million from $39.377 million in 2024[585]. - Research and development expenses decreased to $33.5 million in 2025 from $39.4 million in 2024, primarily due to reduced clinical development expenses[586]. - The company expects substantial expenditures in the foreseeable future as it advances Haduvio through clinical development and regulatory approval processes[574]. - The company emphasizes the importance of establishing healthcare coverage and adequate reimbursement for its products as a critical factor for commercialization success[609]. - The company is focused on expanding its research and development activities and establishing a commercial infrastructure, which will increase headcount and associated costs[609]. General and Administrative Expenses - General and administrative expenses increased to $15.850 million in 2025 from $12.147 million in 2024, an increase of $3.703 million[585]. - General and administrative expenses increased to $15.9 million in 2025 from $12.1 million in 2024, driven by higher outside services, professional fees, and personnel-related expenses[587]. Funding and Capital Needs - The company believes existing cash and marketable securities will fund operations into 2028, but additional capital will be needed for full development and commercialization of Haduvio[606]. - The company has no committed external funding sources and will need to seek additional financing through various means, which may lead to dilution for existing shareholders[608]. - The ability to raise sufficient capital is crucial; failure to do so may lead to delays or abandonment of product development programs[611]. - The company may need to relinquish rights to future revenue streams if additional funds are raised through collaborations or licensing arrangements[611]. Accounting and Financial Reporting - The company’s financial statements are prepared under U.S. GAAP, requiring estimates and assumptions that may impact reported amounts of assets and liabilities[614]. - The company has agreements with CROs and contract manufacturers, with research and development expenses estimated based on service levels and study progress[617]. - Research and development expenses are recognized as incurred, with nonrefundable advance payments deferred and capitalized until the related services are performed[616]. - The company outsources a significant portion of development activities to third parties, with contracts generally cancelable upon 45 to 60 days' notice, indicating non-material non-cancelable obligations[612].

Revenue Performance - Revenue decreased by $1.1 million, or 19.3%, to $4.6 million for the year ended December 31, 2025, from $5.7 million for the year ended December 31, 2024[235]. - Two customers accounted for 70% and 17% of total revenue for the year ended December 31, 2025, compared to three customers accounting for 57%, 18%, and 11% of total revenue for the year ended December 31, 2024[235]. Cost and Expenses - Cost of Goods Sold (COGS) decreased by $2.2 million, or 20.8%, to $8.5 million for the year ended December 31, 2025, from $10.8 million for the year ended December 31, 2024[236]. - Research and development expenses increased to $18.95 million for the year ended December 31, 2025, compared to $16.24 million for the year ended December 31, 2024[232]. - Selling, general and administrative expenses rose to $39.56 million for the year ended December 31, 2025, from $33.51 million for the year ended December 31, 2024[232]. - Total operating expenses increased to $74.81 million for the year ended December 31, 2025, compared to $65.77 million for the year ended December 31, 2024[232]. - Depreciation and amortization expenses increased by $2.5 million, or 48%, to $7.8 million for the year ended December 31, 2025, mainly due to accelerated depreciation related to retired network assets[239]. - Selling, general and administrative expenses rose by $6.1 million, or 18.1%, to $39.6 million during the year ended December 31, 2025, primarily due to a $2.5 million increase in stock-based compensation[238]. Financial Losses - The net loss for the year ended December 31, 2025, was $189.25 million, compared to a net loss of $101.88 million for the year ended December 31, 2024[232]. - Other expenses surged to $106.4 million for the year ended December 31, 2025, compared to $32.2 million in 2024, reflecting significant losses from changes in fair value of derivative liabilities and debt extinguishment[241]. - Net losses for the year ended December 31, 2025, were $189.3 million, compared to $101.9 million in 2024, indicating a substantial increase in financial losses[243]. Cash Flow and Financing - Cash and cash equivalents, along with marketable securities, totaled $152.1 million as of December 31, 2025, with an accumulated deficit of $1.1 billion[243]. - Net cash used in operating activities was $50.7 million for 2025, primarily due to a net loss adjusted for non-cash charges totaling $77.2 million[249]. - Net cash provided by financing activities was $120.5 million in 2025, mainly from the issuance of $190.0 million in Senior Secured Convertible Notes[253]. - As of December 31, 2025, the company had cash and cash equivalents and short-term marketable securities totaling $152.1 million[265]. - The company has $190 million in Senior Secured Convertible Notes due 2028 with a fixed interest rate of 5% per annum, insulating it from interest rate fluctuations[266]. Future Outlook - The company expects to incur additional losses and higher operating expenses for the foreseeable future, necessitating significant cash for ongoing research and development[243]. - Management believes there is minimal credit risk associated with cash and cash equivalents due to the financial soundness of the institutions holding these funds[267]. - The company aims to minimize banking risk by limiting uninsured deposits and investing excess cash in U.S. government securities and money market funds[267]. Market Conditions - Inflation and supply chain challenges have not significantly impacted the company's revenue and cost of services to date, particularly due to moderated inflationary pressure in the U.S. economy[268]. - There is no assurance that future results of operations and financial condition will not be materially impacted by inflation or supply chain challenges[268]. Product Development - The company is evolving its PNT solutions to utilize 5G New Radio positioning reference signals to enhance operational efficiency and service scalability[216]. - Research and development expenses increased by $2.7 million, or 16.7%, to $19.0 million for the year ended December 31, 2025, driven by a $2.8 million increase in non-recurring engineering services[237]. - Interest expense, net, increased to $12.44 million for the year ended December 31, 2025, from $9.40 million for the year ended December 31, 2024[232]. - Interest expense increased by $3.0 million, or 32.4%, to $12.4 million for the year ended December 31, 2025, primarily driven by higher interest and amortization of debt discounts[240].

Financial Performance - ClearPoint Neuro, Inc. announced preliminary, unaudited financial results for Q4 2025 on January 12, 2026[6] - The company reported a revenue increase of 15% year-over-year, reaching $12 million for the fourth quarter[6] - ClearPoint Neuro expects revenue for the full fiscal year 2026 to be in the range of $50 million to $55 million, representing a growth of 25% to 30%[6] - ClearPoint Neuro reported a gross margin of 60% for Q4 2025, an improvement from 55% in Q4 2024[6] - ClearPoint Neuro's cash position at the end of Q4 2025 was $20 million, providing a solid foundation for future growth initiatives[6] User Growth - User data indicated a growth in active users by 20%, totaling 50,000 users by the end of December 2025[6] Market Expansion - The company is focusing on expanding its market presence in Europe, targeting a 10% market share by the end of 2026[6] - The company is exploring potential acquisition opportunities to enhance its technology portfolio and market reach[6] Research and Development - ClearPoint Neuro is investing $5 million in R&D for new product development in 2026, aiming to launch two new products by Q3 2026[6] Marketing Strategy - The company plans to implement new marketing strategies to increase brand awareness and customer engagement in 2026[6]

Financial Performance - Net revenue for Q4 FY 2025 was $648.8 million, an increase of 8.2% from $599.8 million in Q4 FY 2024[5] - Adjusted comparable sales growth for Q4 FY 2025 was 2.8%, driven by growth in conversion and increased eCommerce traffic[5] - Gross profit for Q4 FY 2025 increased 8.6% to $296.5 million, with a gross margin of 45.7%[5] - Net income for Q4 FY 2025 was $41.0 million, compared to $38.6 million in Q4 FY 2024[5] - For FY 2025, net revenue reached $2.4 billion, a 16.8% increase from $2.0 billion in FY 2024[5] - Net revenues for the fiscal year ended December 28, 2025, increased by 16.8% to $2,368,039,000 compared to $2,028,143,000 for the fiscal year ended December 29, 2024[24] - Net income for the fiscal year ended December 28, 2025, was $121,724,000, a 38.4% increase from $87,933,000 in the previous year[24] - Basic net income per share for the fiscal year ended December 28, 2025, was $1.10, compared to $0.80 for the fiscal year ended December 29, 2024[24] - Net income for the fiscal year ended December 28, 2025, was $121,724, up 38.3% from $87,933 in the prior year[29] Profitability Metrics - Adjusted EBITDA for FY 2025 was $240.8 million, representing 10.2% of net revenues[9] - Adjusted EBITDA for the fiscal year ended December 28, 2025, was $240,777, reflecting a 24.1% increase from $193,994 in the prior year[29] - Gross profit for the fiscal year ended December 28, 2025, was $1,081,336,000, representing 45.7% of net revenues, compared to $948,440,000 or 46.8% for the previous year[24] - Selling, general, and administrative expenses for the fiscal year ended December 28, 2025, were $899,873,000, which is 38.0% of net revenues, compared to 40.1% in the previous year[24] - Interest expense for the fiscal year ended December 28, 2025, decreased by 13.7% to $9,091,000 from $10,538,000 in the prior year[24] - Adjusted net income as a percentage of net revenue for the fiscal year was 5.1%, compared to 4.5% in the previous year[29] Liquidity and Cash Flow - Total liquidity at the end of FY 2025 was $177.6 million, including cash and cash equivalents of $53.2 million[9] - Cash flows from operating activities for the fiscal year were $164,474, slightly up from $161,154 in the previous year[27] - The company incurred $83,047 in cash used for investing activities, compared to $78,224 in the prior year[27] - Cash, cash equivalents, and restricted cash at the end of the period were $62,614, down from $80,558 at the beginning of the period[27] - The company paid dividends totaling $425,893 during the fiscal year[27] Future Outlook - The company plans to open approximately 20 new stores in FY 2026, maintaining a total of 209 stores across 26 states[8] - Expected net revenues for FY 2026 are projected to be between $2,600 million and $2,625 million[8] - The company closed its IPO on February 6, 2026, raising approximately $302.7 million in net proceeds[9] Balance Sheet Highlights - Total current assets as of December 28, 2025, were $471,359,000, an increase from $447,919,000 as of December 29, 2024[19] - Total liabilities increased to $1,647,835,000 as of December 28, 2025, from $1,160,834,000 as of December 29, 2024[19] - Operating income for the fiscal year ended December 28, 2025, increased by 42.3% to $167,544,000, up from $117,734,000 in the prior year[24] - Adjusted diluted net income per share for the fiscal year was $1.06, compared to $0.81 in the previous year[31]

Financial Performance - Cash and liquidity increased by approximately 65% during Q4 2025, exceeding $100 million, which is above the high end of the company's guidance range[5] Project Development - The company announced the start of construction of the SOSA Energy Center, a 150 MW/300 MWh battery energy storage system located in Madison County, Texas[6]

Financial Performance - Total revenue for fiscal year 2026 was $3.2 billion, an 8% year-over-year increase, with subscription revenue also increasing by 9% to $3.2 billion[4]. - Billings reached $3.4 billion, marking a 10% year-over-year increase, including a 1.1% positive impact from foreign exchange rates[4]. - Annual Recurring Revenue (ARR) was $3,272 million as of January 31, 2026, reflecting an 8% year-over-year growth[4]. - Total revenue for the three months ended January 31, 2026, was $836.86 million, a 7.8% increase from $776.25 million in the same period of 2025[29]. - Subscription revenue reached $819.00 million for the three months ended January 31, 2026, compared to $757.77 million in the prior year, reflecting a growth of 8.1%[29]. - Net income for the three months ended January 31, 2026, was $90.30 million, compared to $83.49 million in the prior year, representing an increase of 8.7%[29]. - GAAP net income per diluted share was $1.48 on 209 million shares outstanding, compared to $5.08 on 210 million shares in fiscal 2025[4]. - GAAP net income for the three months ended January 31, 2026, was $90,303 thousand, an increase from $83,491 thousand in the same period of 2025, representing an increase of 9.7%[43]. - Non-GAAP net income for the three months ended January 31, 2026, reached $206,138 thousand, up from $184,876 thousand in 2025, reflecting a growth of 11.5%[43]. Cash Flow and Investments - Free cash flow for the fourth quarter was $350.2 million, up from $279.6 million in the same period last year[4]. - Non-GAAP free cash flow for the three months ended January 31, 2026, was $350,199 thousand, compared to $279,570 thousand in the same period of 2025, indicating a significant increase of 25.3%[44]. - The net cash provided by operating activities for the year ended January 31, 2026, was $1,165,007 thousand, an increase from $1,017,272 thousand in 2025, representing a growth of 14.6%[44]. - Cash used in investing activities for Q3 2026 was $33,656,000, compared to $32,291,000 in Q3 2025[35]. - The net cash used in financing activities for the three months ended January 31, 2026, was $(332,586) thousand, compared to $(231,514) thousand in 2025, indicating an increase in cash outflow of 43.7%[44]. Profitability Metrics - Gross profit for the three months ended January 31, 2026, was $667.08 million, up from $616.04 million, resulting in a gross margin of 79.8%[29]. - Non-GAAP gross profit for Q3 2026 was $684,136,000, compared to $638,667,000 in Q3 2025, with a non-GAAP gross margin of 81.8%[38]. - Operating income increased to $87.74 million for the three months ended January 31, 2026, compared to $60.47 million in the same period of 2025, marking a 45% increase[29]. - GAAP income from operations for Q3 2026 was $87,742,000, up from $60,469,000 in Q3 2025, resulting in a GAAP operating margin of 10.5%[41]. - Non-GAAP income from operations for Q3 2026 was $247,127,000, compared to $223,677,000 in Q3 2025, with a non-GAAP operating margin of 29.5%[41]. Balance Sheet Highlights - Total assets as of January 31, 2026, were $4.23 billion, an increase from $4.01 billion as of January 31, 2025[31]. - Total liabilities increased to $2.31 billion as of January 31, 2026, compared to $2.01 billion in the previous year[31]. - Stockholders' equity decreased to $1.92 billion as of January 31, 2026, from $2.00 billion as of January 31, 2025, reflecting an accumulated deficit of $1.86 billion[31]. Future Guidance and Strategic Initiatives - Guidance for total revenue for the three months ending April 30, 2026, is projected between $822 million and $826 million, representing an 8% year-over-year growth[10]. - Non-GAAP gross margin for the upcoming fiscal year is expected to be between 81.5% and 82.0%[10]. - Docusign's AI-native IAM platform generated over $350 million in ARR in 2026, indicating strong market adoption[2]. - Docusign launched several new features, including AI-Assisted Agreement Summaries and AI-Powered eSignature, enhancing its product offerings[6].

Financial Performance - Trevi Therapeutics ended 2025 with $188.3 million in cash, cash equivalents, and marketable securities, with an expected cash runway into 2028[7]. - Trevi reported a net loss of $8.3 million for Q4 2025, an improvement from a net loss of $11.4 million in Q4 2024[10]. Research and Development Expenses - Research and development (R&D) expenses for Q4 2025 decreased to $6.2 million from $9.3 million in Q4 2024, primarily due to reduced clinical development expenses[8]. - For the full year 2025, R&D expenses totaled $33.5 million, down from $39.4 million in 2024, reflecting decreased clinical development costs[12]. General and Administrative Expenses - General and administrative (G&A) expenses for Q4 2025 increased to $4.0 million from $2.9 million in Q4 2024, mainly due to higher professional fees and personnel-related expenses[9]. - G&A expenses for the full year 2025 were $15.9 million, compared to $12.1 million in 2024, driven by increased professional fees and personnel-related expenses[13]. Clinical Trials and Development Plans - The company plans to initiate two pivotal Phase 3 trials for IPF-related chronic cough in 2026, with the first trial expected to enroll approximately 300 patients[11]. - A Phase 2b trial for refractory chronic cough is set to begin in Q2 2026, focusing on the mean change in 24-hour cough frequency as the primary efficacy endpoint[4]. - Trevi aims to conduct an adaptive design Phase 2b trial for non-IPF ILD-related chronic cough in the second half of 2026, pending FDA protocol review[5]. Investigational Therapy - Trevi's investigational therapy Haduvio™ is the first to show a statistically significant reduction in cough frequency in clinical trials for both IPF-related chronic cough and refractory chronic cough[16].

Revenue Composition - Managed Services accounted for approximately 99.3% of revenue in 2025, down from 97.7% in 2024, while SaaS Services represented 0.7% in 2025, compared to 2.3% in 2024[41]. - Revenue for the year ended December 31, 2025, was $31.2 million, a decrease of $4.6 million, or 12.9%, compared to $35.9 million in 2024[201]. - Cost of revenue decreased to $16.2 million, down $5.0 million, or approximately 23.5%, from $21.2 million in 2024, resulting in a gross margin percentage improvement to 48.1% from 40.9%[202]. - Other income net totaled $1.9 million for the year ended December 31, 2025, compared to $2.5 million in the prior year, primarily due to lower investment portfolio income[210]. Market Trends - The global addressable market for the creator economy is projected to rise to $480 billion by 2027, with influencer marketing budgets expected to exceed $9 billion by 2025, tripling from 2019 levels[21]. - The total number of social media users worldwide has surpassed 5 billion, marking a significant shift in the marketing landscape towards the creator economy[21]. Product and Service Development - The Creator Marketplace launched in October 2022, enhancing capabilities for creator discovery and engagement, integrated into the broader technology platform[28]. - In June 2023, the company introduced FormAI, a suite of generative AI tools aimed at improving content creation efficiency for marketers and creators[29]. Customer Focus and Acquisition - The company has a strong focus on customer acquisition, with a dedicated enterprise account management function implemented in 2025 to support existing enterprise-level customers[32]. - Most customers are located in North America, with significant revenue concentration from two customers each accounting for over 10% of total revenue in both 2025 and 2024[43]. Financial Health and Risks - As of December 31, 2025, the company reported an accumulated deficit of $104.3 million and a comprehensive loss of $116,641, which includes $42,326 of income from operations[70]. - The company has incurred significant net losses and negative cash flow from operations for most periods since inception, raising concerns about future profitability[70]. - The company may need to raise additional capital through new financings, which could dilute existing stockholders or restrict borrowing capabilities[71]. - The company faces complexities in revenue recognition due to varying criteria that may lead to significant fluctuations in reported revenue without changes in underlying business or net income[83]. Competition and Market Position - The company faces competition from various influencer marketing services and technology companies, as well as traditional advertising agencies[45]. - The influencer and content marketing market is highly competitive, with potential for reduced pricing and margins due to increased competition[92]. Regulatory and Compliance Issues - The company is subject to various regulations, including the FTC Act and CAN-SPAM Act, which could impose substantial compliance costs and operational changes[54][63]. - The company is subject to evolving government regulations that could increase operational costs and reduce demand for its services[105]. - Compliance with the EU's GDPR could result in fines up to €20 million or 4% of annual global revenues for noncompliance, impacting financial results[110]. - The evolving landscape of privacy laws and regulations increases compliance complexity, which could lead to higher costs and litigation exposure[112]. Operational Challenges - The company relies on third-party social media platforms for influencer marketing, and changes in these platforms' terms or algorithms could adversely affect business operations[99]. - Security breaches could result in significant legal and financial exposure, damaging the company's reputation and user trust[117]. - The company must maintain effective internal controls over financial reporting to ensure timely and accurate financial statements, as failures could lead to a decline in investor confidence and stock price[85]. Stock and Shareholder Information - The company regained compliance with Nasdaq's Bid Price Rule in 2023 by executing a 4-for-1 reverse stock split after falling out of compliance in 2022[138]. - The company has authorized a stock repurchase program allowing for the repurchase of up to $10.0 million of its common stock, with $8.6 million remaining available for purchase as of June 16, 2025[179]. - The company has never paid cash dividends and does not anticipate doing so in the foreseeable future, intending to retain earnings for business use[176]. Strategic Initiatives - The Company completed the divestiture of Hoozu Holdings on December 18, 2024, as part of a strategic realignment to focus on core enterprise customers[187]. - The Company executed a strategic realignment in 2024 aimed at accelerating profitability and improving operational focus, including targeted workforce reductions[188]. - The Company recorded a $4.0 million impairment of goodwill related to prior acquisitions in September 2024 due to changes in executive management[205]. Employee and Workforce Management - The company has a remote workforce of 75 active full-time employees as of December 31, 2025, reflecting a strategic reduction in human capital costs[66]. - The company faces intense competition for qualified personnel, which could adversely affect its ability to manage operations and achieve growth objectives[135].

Financial Performance - For the year ended December 31, 2025, NextNav reported revenue of $4.573 million, a decrease of 19.4% compared to $5.669 million in 2024[16] - The company's total operating expenses for 2025 were $74.805 million, up 13.8% from $65.767 million in 2024[16] - NextNav's net loss for 2025 was $189.253 million, compared to a net loss of $101.879 million in 2024, reflecting an increase of 85.4%[16] Cash and Debt Position - As of December 31, 2025, NextNav had cash and cash equivalents of $44.757 million, an increase from $39.330 million at the end of 2024[14] - The company reported a net long-term debt of $273.6 million, which includes a derivative liability of $115.8 million[4] Asset Growth - NextNav's total assets increased to $247.019 million in 2025, up from $161.740 million in 2024, representing a growth of 52.7%[14] Strategic Initiatives - The company announced the commencement of localized operation of the world's first 5G-powered PNT Network for temporary testing purposes in December 2025[10] - NextNav expanded its partnership with Japan's MetCom in December 2025, indicating a strategic move towards global market demand for PNT solutions[10] Leadership Changes - The company appointed Lisa Hook as Lead Independent Director in February 2026, enhancing its leadership team[10] Regulatory Outlook - NextNav is optimistic about the FCC's progress towards a Notice of Proposed Rulemaking (NPRM), which is crucial for its regulatory strategy[3]